AU2020243431B2 - A2/NY-ESO-1 specific T cell receptors and uses thereof - Google Patents

A2/NY-ESO-1 specific T cell receptors and uses thereof

Info

Publication number
AU2020243431B2
AU2020243431B2 AU2020243431A AU2020243431A AU2020243431B2 AU 2020243431 B2 AU2020243431 B2 AU 2020243431B2 AU 2020243431 A AU2020243431 A AU 2020243431A AU 2020243431 A AU2020243431 A AU 2020243431A AU 2020243431 B2 AU2020243431 B2 AU 2020243431B2
Authority
AU
Australia
Prior art keywords
tcr
cells
seq
cell
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020243431A
Other languages
English (en)
Other versions
AU2020243431A1 (en
Inventor
George Coukos
Melita IRVING
Olivier Michielin
Vincent Zoete
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LUDWIG INSTITUTE FOR CANCER RESEARCH Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU2020243431A1 publication Critical patent/AU2020243431A1/en
Application granted granted Critical
Publication of AU2020243431B2 publication Critical patent/AU2020243431B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
AU2020243431A 2019-03-18 2020-03-17 A2/NY-ESO-1 specific T cell receptors and uses thereof Active AU2020243431B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819988P 2019-03-18 2019-03-18
US62/819,988 2019-03-18
PCT/IB2020/000140 WO2020188348A2 (en) 2019-03-18 2020-03-17 A2/ny-eso-1 specific t cell receptors and uses thereof

Publications (2)

Publication Number Publication Date
AU2020243431A1 AU2020243431A1 (en) 2021-09-30
AU2020243431B2 true AU2020243431B2 (en) 2025-12-18

Family

ID=70465122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020243431A Active AU2020243431B2 (en) 2019-03-18 2020-03-17 A2/NY-ESO-1 specific T cell receptors and uses thereof

Country Status (7)

Country Link
US (2) US12473346B2 (https=)
EP (1) EP3941939A2 (https=)
JP (1) JP7680032B2 (https=)
CN (1) CN113906140B (https=)
AU (1) AU2020243431B2 (https=)
CA (1) CA3134102A1 (https=)
WO (1) WO2020188348A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4217738A1 (en) * 2020-09-27 2023-08-02 Genentech, Inc. High throughput multiparametric immune cell engager screening assay
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297093A1 (en) * 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
US20120071420A1 (en) * 2006-09-26 2012-03-22 Immunocore Limited Modified t cell receptors and related materials and methods
WO2017087723A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5617900A (en) 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
SI2804617T1 (sl) 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
CN108456247A (zh) 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071420A1 (en) * 2006-09-26 2012-03-22 Immunocore Limited Modified t cell receptors and related materials and methods
US20100297093A1 (en) * 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
WO2017087723A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBBINS PAUL F ET AL: "Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 180, no. 9, 1 May 2008, pages 6116 - 613 *

Also Published As

Publication number Publication date
AU2020243431A1 (en) 2021-09-30
EP3941939A2 (en) 2022-01-26
US12473346B2 (en) 2025-11-18
WO2020188348A2 (en) 2020-09-24
US20220152109A1 (en) 2022-05-19
JP2022525925A (ja) 2022-05-20
JP7680032B2 (ja) 2025-05-20
US20260103503A1 (en) 2026-04-16
CN113906140B (zh) 2025-01-28
CA3134102A1 (en) 2020-09-24
WO2020188348A3 (en) 2020-12-17
CN113906140A (zh) 2022-01-07

Similar Documents

Publication Publication Date Title
AU2020243431B2 (en) A2/NY-ESO-1 specific T cell receptors and uses thereof
JP7846963B2 (ja) 生物学的に関連する直交サイトカイン／受容体対
EP3490585B1 (en) Immunomodulatory polypeptides and related compositions and methods
JP7178906B2 (ja) ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
US12528847B2 (en) Heterodimeric inactivatable chimeric antigen receptors
JP2024069500A (ja) 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
JP2024500847A (ja) 適合可能な受容体特異性を有するキメラ抗原受容体システム
JP2019516350A (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
CN112567024A (zh) 表达pd-l1嵌合抗原受体的nk细胞消除pd-l1阳性恶性肿瘤
KR20190003938A (ko) 면역치료를 위한 변형된 세포
KR20170068598A (ko) 입양 세포 치료에서 복용을 위한 방법 및 조성물
EP3288569A2 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CA3031846A1 (en) Chimeric antigen receptor
EP4255922A1 (en) Genetically engineered cells and uses thereof
US12570730B2 (en) Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors
US20230030680A1 (en) Chimeric gmcsf-il18 receptor
US20230414660A1 (en) Pd-1 decoy variants for immunotherapy
KR20200056333A (ko) 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
US20240216427A1 (en) Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)
US20250346649A1 (en) Zip cytokine receptors
Mangolini et al. Highly potent novel multi-armoured IL13Rα2 CAR-T subverts the immunosuppressive microenvironment of Glioblastoma
HK40058918A (en) A2/ny-eso-1 specific t cell receptors and uses thereof
HK40058918B (zh) A2/ny-eso-1特异性t细胞受体及其用途
US20240207319A1 (en) Compositions and methods for immunotherapy
WO2024238938A1 (en) Modulation of the btla-hvem axis to enhance adoptive cell transfer immunotherapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)